Online Inquiry
Recombinant Serine/threonine-protein kinase B-raf (BRAF), partial
SPP-00709
| Size | Price |
| 20 μg | Online Inquiry |
| 100 μg | Online Inquiry |
| 500 μg | Online Inquiry |
| Target Information | |
|---|---|
| Species | Coturnix japonica |
| Target Name | B-Raf |
| UniProt No. | P34908 |
| Subcellular Location | Nucleus, Cytoplasm, Cell membrane |
| Tissue Specificity | Expressed preferentially in neural tissue. |
| Gene Abbr. | Braf |
| Full Name | Braf transforming gene |
| Introduction | A-Raf, B-Raf, and c-Raf (Raf-1) are the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. Activation of c-Raf is the best understood and involves phosphorylation at multiple activating sites including Ser338, Tyr341, Thr491, Ser494, Ser497, and Ser499. p21-activated protein kinase (PAK) has been shown to phosphorylate c-Raf at Ser338, and the Src family phosphorylates Tyr341 to induce c-Raf activity. Ser338 of c-Raf corresponds to similar sites in A-Raf (Ser299) and B-Raf (Ser445), although this site is constitutively phosphorylated in B-Raf. Inhibitory 14-3-3 binding sites on c-Raf (Ser259 and Ser621) can be phosphorylated by Akt and AMPK, respectively. While A-Raf, B-Raf, and c-Raf are similar in sequence and function, differential regulation has been observed. Of particular interest, B-Raf contains three consensus Akt phosphorylation sites (Ser364, Ser428, and Thr439) and lacks a site equivalent to Tyr341 of c-Raf. Research studies have shown that the B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma. Six residues of c-Raf (Ser29, Ser43, Ser289, Ser296, Ser301, and Ser642) become hyperphosphorylated in a manner consistent with c-Raf inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders c-Raf unresponsive to subsequent activation events. |
| Product Details | |
|---|---|
| Product Type | Recombinant Protein |
| Storage & Handling | |
|---|---|
| Storage Temp. | Store at -20 °C upon receipt unless otherwise instructed. |
| Handling | Aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.